Maze Therapeutics, Inc.
Maze Therapeutics, Inc. (NASDAQ: MAZE) is a clinical-stage biopharmaceutical company focused on developing precision medicines for kidney and metabolic diseases using human genetic insights. The company's website is www.mazetherapeutics.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Maze Therapeutics, Inc. does
In the company’s own words
Maze Therapeutics, Inc. (NASDAQ: MAZE) is a clinical-stage biopharmaceutical company focused on developing precision medicines for kidney and metabolic diseases using human genetic insights. The company's website is www.mazetherapeutics.com.
The company operates through its proprietary Compass platform, which enables the identification and characterization of genetic variants associated with health and disease, followed by a process called variant functionalization to determine how these variants drive disease risk or protection in specific patient populations. This platform integrates genetic data with clinical information to inform drug discovery and development across all phases, including clinical trial design.
Maze Therapeutics maintains two wholly-owned clinical programs. MZE829, the company's most advanced candidate, is an oral small molecule inhibitor of apolipoprotein L1 (APOL1) in Phase 2 development for APOL1-mediated kidney disease (AMKD), a genetically defined subset of chronic kidney disease affecting approximately one million patients in the United States. MZE782, the second program, is a small molecule inhibitor targeting SLC6A19 being developed for phenylketonuria (PKU) and chronic kidney disease (CKD), with Phase 2 trials planned for 2026.
Beyond its internal pipeline, Maze Therapeutics has demonstrated the versatility of its Compass platform through strategic partnerships. The company licensed MZE001, a glycogen synthase inhibitor for Pompe disease, to Shionogi for $150 million upfront plus milestone payments and royalties. Additional partnered programs include ATXN2 for amyotrophic lateral sclerosis (licensed to Neurocrine Biosciences), UNC13A for neurological diseases (licensed to Trace Neuroscience), and ANGPTL7 for glaucoma (developed through Broadwing, a joint venture with Alloy Therapeutics in which Maze holds approximately 48% equity).
As of March 2026, the company had approximately 49.7 million shares of common stock outstanding. Maze Therapeutics is classified as a smaller reporting company and an emerging growth company under Securities and Exchange Commission definitions. The company has not generated product revenue and expects to incur continued operating losses as it advances its clinical development programs and research initiatives.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1842295
- SIC
- 2836
Financial performance, year by year
Fiscal 2025–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Maze Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Maze Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Maze Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Maze Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Maze Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”